AMD (age-related macular degeneration) is the major cause of blindness in the western world, associated with the formation of extracellular deposits called drusen in the macula, i.e. the central region of the retina. These drusen contain cellular debris and proteins, including components of the complement system such as the regulator CFH (complement factor H); dysregulation of complement is thought to play a major role in the development of AMD. CFH acts through its capacity to recognize polyanionic structures [e.g. sulfated GAGs (glycosaminoglycans)] found on host tissues, and thereby inactivates any C3b that becomes deposited. Importantly, a common polymorphism in CFH (Y402H) has been strongly associated with an increased risk of AMD. This polymorphism, which causes a tyrosine to histidine coding change, has been shown to alter the binding of CFH to sulfated GAGs, as well as to other ligands including C-reactive protein, necrotic cells and bacterial coat proteins. Of these, the change in the GAG-recognition properties of CFH is likely to be of most significance to AMD. Recent research has revealed that the disease-associated 402H allotype interacts less well (compared with 402Y) with binding sites within the macula (e.g. Bruch's membrane), where the GAGs heparan sulfate and dermatan sulfate play a major role in mediating the interaction with CFH. Reduced binding of the 402H allotype could result in impaired regulation of complement leading to chronic local inflammation that may contribute to the accumulation of drusen and thus the initiation, development and progression of AMD.
Introduction
AMD (age-related macular degeneration) is the leading cause of blindness in the western world, affecting approximately 50 million people worldwide. The prevalence of this condition is predicted to rise as the elderly population expands; indeed, in the U.S.A., it was estimated that there will be a 50% increase in the number of affected individuals between 2004 and 2020 [1] . This debilitating disease can be subdivided into neovascular ('wet') and atrophic ('dry') AMD [2] , both of which are preceded by the formation of drusen. This particulate material accumulates between the RPE (retinal pigment epithelium) and the Bruch's membrane, where the latter separates the RPE and neurosensory retina from the blood vessels in the choroid (reviewed in [3] ). Drusen are composed of a large variety of constituents, e.g. debris from the degeneration of RPE cells, lipids and many proteins of the complement system [4] [5] [6] [7] . The finding that drusen contained markers of complement activation led to the hypothesis that dysregulation of complement plays a role in the development of AMD [7, 8] . It should be noted that the complement cascade forms part of the innate immune system, protecting against micro-organisms and mediating the clearance of cellular debris from host tissues. In this regard, drusen were also found to contain complement regulators [7] , including the plasma protein CFH (complement factor H), which has been implicated as having a role in host/non-host discrimination [9, 10] .
CFH and its association with AMD
Several major studies have linked a polymorphism in the CFH gene (Y402H) with an elevated risk of developing AMD [11] [12] [13] [14] [15] ; this polymorphism, which is found in ∼ 35% of individuals of European descent, results in the replacement of a tyrosine residue by a histidine residue at position 402 (equivalent to 384 in the mature protein) [16, 17] . Although other risk and protective polymorphisms have been identified in CFH (see [18] ) and in other complement components (e.g. in factor B [19] ), the Y402H polymorphism is currently considered to represent the major genetic risk factor for AMD [20] ; some of these influence the activation of complement in blood, but the effects of the Y402H polymorphism appear to be mediated locally in tissues [20] .
The CFH Y402H polymorphism has also been linked to DDD (dense deposit disease; previously referred to as membranoproliferative glomerulonephritis type II), a condition that can lead to renal failure and is believed to result from the unchecked over-activation of the complement system (see [21] ). In both of these diseases, complement-containing lesions form next to regions of GAG (glycosaminoglycan)-rich extracellular matrix (i.e. Bruch's membrane in AMD and the glomerular basement membrane in DDD). Interestingly, many patients suffering from DDD develop ocular drusen indistinguishable from those observed in AMD. More controversially, the Y402H polymorphism has been reported to be associated with both myocardial infarction [22] and Alzheimer's disease [23] , although other studies suggest this may not be the case [24, 25] .
The function and structure of CFH
CFH is a serum glycoprotein, mainly produced in the liver, that functions as a regulator of the alternative pathway of complement. For example, it acts as a cofactor for the factor I-mediated proteolytic inactivation of C3b (the central complement component) to iC3b. It is believed that CFH can discriminate between host and non-host surfaces through its recognition of (and binding to) polyanionic structures on host tissues [9, 10] (e.g. sulfated GAGs; see below). This surfaceassociated CFH can interact with C3b that becomes deposited (generated via continual low-level tick-over of C3 in the fluid phase) and thus prevents the amplification of the complement system by promoting its inactivation. On the other hand, on activator surfaces (e.g. bacteria) where CFH does not bind, amplification can occur through the production of C3 convertase enzymes, leading to opsonization of the surface with many molecules of C3b, i.e. targeting it for phagocytosis. Thus inappropriate complement activation on host tissues is prevented by the presence of CFH or one of its cell-surface homologues {i.e. DAF (decay-accelerating factor), MCP (membrane cofactor protein) and CR1 (complement receptor 1) [26] }; it should be noted, however, that CFH is the only one of these regulators present in the extracellular matrix.
It is well established that CFH can bind to heparin [10, [27] [28] [29] [30] [31] [32] [33] , a highly sulfated polysaccharide secreted by mast cells [34] . On this basis, it has been widely assumed that CFH would interact with the related GAG HS (heparan sulfate) present on all cell surfaces and extracellular matrices, although there was little direct evidence for this. Our recent studies have demonstrated that HS [and DS (dermatan sulfate)] in human macula does mediate the binding of CFH and thus may contribute to host recognition [35] .
The CFH protein comprises 20 contiguous CCP (complement control protein) modules [17] (sometimes referred to as SCRs or Sushi domains). The three-dimensional structures of the majority of these have now been determined, including the two heparin-binding sites, i.e. 6-8 (illustrated in Figure 1A ) and 19-20 [31] . The AMD-associated Y402H polymorphism occurs in CCP7 [16, 17] and has been shown to have a major effect on the heparin-binding specificity [55] No observable differences between the binding of either variant to: fhBP in Neisseria meningitidis [56] Cultured RPE cells [40] of CFH [30, 32] , as will be discussed in more detail later. Polymorphisms/mutations causing coding changes within the C-terminal heparin-binding domain of CFH (CCPs 19-20) have been linked with another disease, i.e. atypical haemolytic uraemic syndrome, a leading cause of paediatric kidney failure (see references at http://www.fh-hus.org).
Effect of the Y402H polymorphism on the binding of other CFH ligands
The binding of CFH to heparin is not the only interaction affected by the Y402H polymorphism. As summarized in Table 1 , differential binding of the CFH 402H and 402Y variants has been observed for a number of ligands, for example CRP (C-reactive protein) [36] [37] [38] [39] [40] and necrotic cells [36] that are both constituents of drusen; other interactions appear to be unaffected (e.g. with cultured RPE cells [40] ). CRP is an acute-phase protein, in that its concentration in blood rises dramatically during inflammation, e.g. it is increased in the circulation and choroid of patients with AMD [41, 42] . Although the exact role of CRP during an immune response is not entirely understood, it is believed to bind phosphocholine on the surfaces of some microbes and on the surface of necrotic cells where it activates complement via the classical pathway by recruiting C1q [43] . However, CRP also interacts with soluble complement regulators, such as CFH, that would decrease the amplification of complement. It is because of its dual activating/inhibiting role that it has been suggested that CRP contributes to the complementmediated clearance of apoptotic/necrotic cells as well as simultaneously dampening down an aberrant inflammatory response that may otherwise cause further damage to already compromised host tissues [44] . A number of studies have identified that the CFH 402H variant binds less well to CRP compared with the 402Y form (see references in Table 1 ), which could lead to increased complement amplification (see [36] ). However, it should be noted that CFH has been found to only bind denatured CRP [45] (which might be caused by its immobilization, for example, in in vitro binding assays), although others have reported that denatured CRP is present on the surface of necrotic cells and can bind CFH [46] . Interestingly, greater binding of 402H than 402Y to necrotic cells was seen [36] , indicating that ligands other than CRP (that binds better to 402Y) are involved in the interaction with CFH on dying cells (e.g. DNA; see Table 1 ). Furthermore, the enhanced accumulation of 402H on necrotic cells is likely to lead to increased inhibition of complement and perhaps reduced clearance [36] .
The 402H variant of CFH has been found to bind significantly less well compared with the 402Y allotype to the Streptococcus M protein expressed on the surface of Streptococcus pyogenes (see Table 1 ), which is known to be involved in invasion and immune evasion by recruiting CFH, through its interaction with the CCP7 domain [47] . Thus homozygous 402H individuals would be expected to be less susceptible to GAS (group A Streptococcal) infections than those carrying the 402Y haplotype due to unimpaired phagocytosis of the bacteria (see [48] ). Thus the prevalence of the 402H variant in the human population may be attributable to its protective effect against GAS infections during early age. It is tempting to speculate that the frequency of the 402H allele became greatly increased in the European population because it was a survival factor during bacterial pandemics such as the bubonic plague.
The structure and diversity of HS
GAGs are unbranched polysaccharides composed of repeating disaccharide units that differ from one another in their disaccharide composition, linkages and levels of sulfation [34, 49, 50] . Most GAGs (e.g. DS and HS) are found in tissues associated with a core protein, i.e. as proteoglycans. The two exceptions to this are heparin (a highly sulfated GAG, related to HS, that is secreted by mast cells in response to inflammatory stimuli) and hyaluronan, a non-sulfated, high-molecular-mass polysaccharide found ubiquitously in all tissues [51] ; the highly sulfated regions of HS (so called S domains) resemble heparin in structure. HS consists of repeating disaccharide units that are composed of an uronic acid [GlcA (D-glucuronic acid) or IdoA (L-iduronic acid)] and a derivative of Glc (glucosamine). As can be seen from Table 2 , both glucuronate and iduronate can be sulfated at the 2-position (to form GlcA2S and IdoA2S respectively), whereas glucosamine can be O-sulfated at the 3-and 6-positions, and can also be N-sulfated (GlcNS), N-acetylated (GlcNAc) or unsubstituted (GlcNH 3 ) (for a review see [49] ); all glycosidic bonds are α1-4, except for the β1-4 linkages at the reducing side of GlcA. Importantly, there is considerable variability in the level and pattern of sulfation seen in heparin/HS such that the repertoire of sequences made by a particular cell or tissue has been described as its heparanome (see [52] ); indeed there are at least 32 different disaccharide units present in heparin/HS, giving rise to a very large number of sequence permutations (see Table 2 ). Given that HS chains are typically 50-200 disaccharides in length, there is a huge potential to generate protein-binding sites with different specificities and provide fine regulation of protein function in particular tissue microenvironments. Mulloy, personal communication). The four possible sulfation positions are underlined in the central iduronic acid/N-sulfated glucosamine disaccharide. The level of binding (relative to the parental, unmodified heparin) was determined from the curves reported in [30, 32] , where ↔ means no significant change and ↓-↓↓↓↓ denotes the magnitude of the decrease.
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The interaction of CFH with sulfated GAGs
Previously, it has been reported that the Y402H polymorphism in CFH (i.e. in fragments containing CCP7) altered its heparin-binding properties [30, 33, 37, 40] . In particular, our work demonstrated that the 402H and 402Y variants (in the context of recombinant proteins comprising CCP modules 6-8) had differential binding to heparin, where the affinity of the interaction was dependent on the source of heparin used [30] . Additionally, binding assays conducted with selectively de-sulfated heparin preparations (as models of HS) revealed that the AMD-associated 402H variant was more sensitive to changes in sulfation that the 402Y allotype (Table 2) ; the presence of N-, 2-O-and 6-O-sulfates is necessary for high affinity binding to 402H, whereas the removal of 2,6-O-or N-sulfates had little or no effect on the interaction with 402Y. These results clearly indicate that the heparin/HS specificities of the two variants are distinct [30] . The three-dimensional structure of the CCP6-8 region of CFH (i.e. for the 402H variant) in complex with SOS (sucrose octasulfate) (see Figure 1A ) was determined by X-ray crystallography [32] ; NMR analyses indicated that SOS binds in a similar way as a heparin tetrasaccharide, indicating that it is a good mimetic for highly sulfated GAGs. The histidine amino acid at position 402 in CCP7 was found to be hydrogen-bonded to a sulfate group in the SOS, providing further evidence that this residue is directly involved in GAG binding. Importantly, this mode of ligand recognition was not possible when a tyrosine residue was at this position [32] , consistent with NMR studies on the 402H and 402Y variants in the isolated CCP7 domain [33] . The structural studies on CCP6-8 also identified additional GAG-binding sites in CCP6, CCP7 and the linker between CCPs 7 and 8 [32] . These, along with the binding site involving residue 402, are found in a groove on the protein's surface and probably represent sub-sites in the interaction with an extended sequence of heparin/HS of ∼18 saccharides in length. Overall, these structural studies provide a plausible molecular explanation for the greater requirement of sulfation in the interaction of the 402H variant (compared with 402Y) with heparin/HS.
CFH-binding sites in human eye tissue
As described above, the Y402H polymorphism is likely to have a major effect on the specificity of CFH for heparin/HS and thus could influence its binding to sulfated GAGs in tissues. Our recent studies show that this is indeed the case within the macula region of normal (i.e. non-AMD) human eyes [35] . The binding sites for the 402H and 402Y variants of CFH were visualized (by immunofluorescence) using these proteins labelled with different fluorophores, either in the context of our CCP6-8 construct or in the full-length CFH purified from genotypic individuals. This revealed that, although there was no difference in the level of binding of the exogenously applied variants to the RPE, there was significantly less binding (∼2-fold) of the 402H allotype to Bruch's membrane (and the choroidal blood vessels) than that seen for the 402Y variant ( Figure 1B) . Treatment of the macula tissue sections, for example with GAG-degrading enzymes, demonstrated that HS (and to a lesser extent DS) are major constituents of these CFH-binding sites; removal of other GAGs, i.e. hyaluronan and chondroitin (4 and 6) sulfates, had little effect, consistent with binding assays demonstrating that the CCP6-8 region of CFH interacts with HS and DS, but not with chondroitin-4-sulfate, chondroitin-6-sulfate or hyaluronan. Importantly, these experiments [35] showed that different HS structures are recognized by the 402H and 402Y CFH variants in line with our earlier biochemical characterization [30, 32] (see above).
The similarity of the staining patterns for the CCP6-8 and full-length proteins (e.g. with a lower level of binding of the 402H variant in Bruch's membrane) indicates that the GAG-recognition site in CCPs 6-8 plays a major role in the localization of CFH within the macula [35] . The apparently contradictory finding that the CCP19-20 region is likely to represent the major binding site for the interaction of CFH in other tissues (e.g. kidney) (see [18] ) can be explained by the tissue-specific biosynthesis of GAGs [49, 52] , i.e. with distinct compositions/sequences differentially recognized by the two CFH heparin/HS-binding sites [35] . The expression of distinct GAG structures in different tissues may also explain why the effects of the Y402H polymorphism are mainly restricted to the human eye.
Immunolocalization of endogenous CFH revealed that it had an essentially identical distribution to the CFH-binding sites and that removal of HS and DS caused a significant reduction in staining [35] . Therefore, our studies provide good evidence that CFH does interact with sulfated GAGs in human eye tissue and that the AMD-associated Y402H polymorphism alters how these are recognized.
A disease mechanism for AMD?
As described above, we have found that the AMD-associated 402H variant of CFH has a lower capacity to bind the HS/DS GAG structures present in Bruch's membrane compared with the non-disease 402Y allotype [35] ; we have not yet explored whether this translates to a reduced level of CFH in the macula of individuals who carry the 402H haplotype; however, these studies are on-going. A consequence of less CFH present on the Bruch's membrane (i.e. an extracellular matrix devoid of other alternative pathway regulators) would be impaired regulation of complement at this site and, as can be seen from Figure 1 (C), increased complement turnover would lead to chronic local inflammation. This hypothesis is consistent with the current consensus that complement dysregulation at the RPE-choroid interface is a major feature of the pathobiology of AMD (see [7] ). Our suggestion of a local change in the binding of CFH, e.g. in the Bruch's membrane, is a reasonable disease mechanism given that no age-or AMD-related alteration in the expression of complement-related genes has been observed [7] . In this regard, it is possible that age-related changes in GAG structure (as have been observed in various tissues; see [30, 53] ) could contribute to a reduction in the binding of the 402H variant of CFH over time (e.g. a decrease in the sulfation of HS). Importantly, it should be noted that our studies on the visualization of CFH-binding sites were performed on non-AMD eye tissues from donors of 60+ years [35] . Therefore the fundamental difference in the binding of the CFH 402H and 402Y variants to Bruch's membrane (that we observed in these normal samples), resulting from a functional alteration in their GAG-binding properties, may play a particularly important role in the initiation and development of AMD. However, the effect of the Y402H polymorphism on the interaction of CFH with other ligands, e.g. CRP and necrotic cells (see Table 1 ), could affect the amount of CFH protein that binds to drusen and, thus, also contribute to AMD development/progression (e.g. via altered clearance mechanisms).
Concluding remarks
The Y402H polymorphism in CFH, concluded to be a major genetic risk factor for AMD, has a profound effect on the GAG-binding properties of the CFH protein. We have found that this greatly affects the recognition of sulfated GAGs within the macula region of the human eye, leading to the proposal of a new disease mechanism for AMD. Clearly, further research is now needed to test this and the other hypotheses described above to provide a more complete understanding of the biochemical and pathological processes that underlie this major form of blindness.
